Ergoteles LLC lowered its position in Applied Therapeutics, Inc. (NASDAQ:APLT – Get Rating) by 40.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 51,685 shares of the company's stock after selling 34,915 shares during the quarter. Ergoteles LLC owned 0.11% of Applied Therapeutics worth $48,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in APLT. Franklin Resources Inc. boosted its holdings in Applied Therapeutics by 199.3% in the second quarter. Franklin Resources Inc. now owns 4,775,484 shares of the company's stock valued at $4,528,000 after acquiring an additional 3,179,934 shares during the last quarter. FMR LLC boosted its holdings in Applied Therapeutics by 343.6% in the second quarter. FMR LLC now owns 4,007,283 shares of the company's stock valued at $3,800,000 after acquiring an additional 3,103,990 shares during the last quarter. Laurion Capital Management LP acquired a new position in Applied Therapeutics in the second quarter valued at $328,000. Point72 Asset Management L.P. lifted its stake in shares of Applied Therapeutics by 11.2% during the second quarter. Point72 Asset Management L.P. now owns 2,835,000 shares of the company's stock worth $2,688,000 after purchasing an additional 286,000 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of Applied Therapeutics by 1,503.4% during the first quarter. Renaissance Technologies LLC now owns 282,200 shares of the company's stock worth $595,000 after purchasing an additional 264,600 shares in the last quarter. Institutional investors and hedge funds own 62.94% of the company's stock.
Get Applied Therapeutics alerts:Applied Therapeutics Price Performance
Shares of APLT opened at $0.93 on Friday. The stock's 50-day moving average is $1.01 and its two-hundred day moving average is $0.97. The stock has a market cap of $44.62 million, a PE ratio of -0.28 and a beta of 1.90. Applied Therapeutics, Inc. has a 12 month low of $0.50 and a 12 month high of $2.73.
Applied Therapeutics Profile
(Get Rating)
Applied Therapeutics, Inc is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.
Further Reading
- Get a free copy of the StockNews.com research report on Applied Therapeutics (APLT)
- Fossil Group: Should You Bet On Consumer Discretionary In 2023?
- BJ's Wholesale Club Stock Moves Higher After Strong Results
- Monthly Realty Income is About to Get Bigger
- 3 Large Cap Dividend Challengers for Millennial Investors
- Sea Ltd Is On The Verge Of A 100% Rally, Should You Buy?
Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.